The Greater Cannabis Company, Inc. (GCAN)

OTCMKTS: GCAN · Delayed Price · USD
0.0007
+0.0001 (8.33%)
Mar 28, 2023, 3:27 PM EDT - Market closed
Market Cap 434.62K
Revenue (ttm) n/a
Net Income (ttm) -509,198
Shares Out 668.64M
EPS (ttm) -0.00
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 23,801
Open 0.0005
Previous Close 0.0006
Day's Range 0.0005 - 0.0007
52-Week Range 0.0004 - 0.0032
Beta 1.27
Analysts n/a
Price Target n/a
Earnings Date n/a

About GCAN

The Greater Cannabis Company, Inc. engages in the development and commercialization of cannabinoid therapeutics. It offers an oral transmucosal patch platform, which provides loaded actives absorbed by the buccal mucosa into the body. The company was founded in 2014 and is based in Baltimore, Maryland. [Read more]

Sector Healthcare
CEO Mr. Aitan Zacharin
Employees 1
Stock Exchange OTCMKTS
Ticker Symbol GCAN
Full Company Profile

Financial Performance

In 2021, GCAN's revenue was $12,630, a decrease of -73.71% compared to the previous year's $48,044. Losses were -$602,226, -36.69% less than in 2020.

Financial Statements

News

GCANRx Announces Submission of Phase 2 Clinical Trial Application to Treat Autism Related Spectrum Disorders

BALTIMORE, Oct. 07, 2022 (GLOBE NEWSWIRE) -- Greater Cannabis Company, Inc. (“GCANRx” or the “Company”) (OTC: GCAN) a biopharmaceutical company pioneering development of next generation cannabinoid th...

6 months ago - GlobeNewsWire

GCANRx Strategic Advisor Dr. Adi Aran to be Interviewed by Dr. Sanjay Gupta on CNN Cannabis Special

The 6 th Installment in the Award-winning Series by Dr. Sanjay Gupta will Air on Sunday, December 19 th at 9pm ET

1 year ago - GlobeNewsWire

GCANRx Appoints Renowned Cannabinoid Researcher Dr. Adi Aran as Strategic Advisor

Dr. Aran will be focused on furthering development of the therapeutic pipeline, advancing the clinical study program and supporting IP and regulatory strategies.

1 year ago - GlobeNewsWire

GCANRx Announces Initiation of Preclinical Study for Neuropsychiatric Cannabinoid Therapy

BALTIMORE, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Greater Cannabis Company, Inc. (“GCANRx” or the “Company”) (OTC: GCAN) a biopharmaceutical company pioneering development of next generation cannabinoid th...

1 year ago - GlobeNewsWire

GCANRx Signs Licensing Agreement with Shaare Zedek Scientific for Innovative Neuropsychiatric Cannabinoid Therapy

BALTIMORE, Aug. 19, 2021 (GLOBE NEWSWIRE) -- Greater Cannabis Company, Inc. (“GCANRx” or the “Company”) (OTCQB: GCAN) a cannabis innovator specializing in the development of pharmaceutical and consume...

1 year ago - GlobeNewsWire

GCANRx Announces Collaboration with Renowned Cannabis Research Lab

BALTIMORE, March 16, 2021 (GLOBE NEWSWIRE) -- Greater Cannabis Company ( OTCQB: GCAN), an innovator in the development and commercialization of cannabinoid delivery systems and cannabinoid products i...

2 years ago - GlobeNewsWire

Greater Cannabis Company Announces Retirement of Remaining Convertible Debt

BALTIMORE, MD, Jan. 20, 2021 (GLOBE NEWSWIRE) -- The Greater Cannabis Company (GCAN), an innovator in the development and commercialization of cannabinoid delivery systems and cannabinoid products tod...

2 years ago - GlobeNewsWire